Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > AOPEP(Gene name) > Human
  • Add your favorite
  • AOPEP (Gene name),
  • Aminopeptidase O (Protein name ),  AMPO_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Feedback
  • Gene name:
    AOPEP(C9orf3;ONPEP);
    Protein name:
    Aminopeptidase O(AP-O);
    Alternative:

    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    N/A
    Function:
    Aminopeptidases catalyze the hydrolysis of amino acid residues from the N-terminus of peptide or protein substrates. Able to cleave angiotensin III to generate angiotensin IV, a bioactive peptide of the renin-angiotensin pathway. Not able to cleave angiotensin I and angiotensin II. May play a role in the proteolytic processing of bioactive peptides in tissues such as testis and heart.
    Subcellular Location:
    Cytoplasm
    Protein Attributes:
    Sequence length:
    819
    Sequence:
    50:
    MDIQLDPARD | DLPLMANTSH | ILVKHYVLDL | DVDFESQVIE | GTIVLFLEDG | 
    100:
    NRFKKQNSSI | EEACQSESNK | ACKFGMPEPC | HIPVTNARTF | SSEMEYNDFA | 
    150:
    ICSKGEKDTS | DKDGNHDNQE | HASGISSSKY | CCDTGNHGSE | DFLLVLDCCD | 
    200:
    LSVLKVEEVD | VAAVPGLEKF | TRSPELTVVS | EEFRNQIVRE | LVTLPANRWR | 
    250:
    EQLDYYARCS | QAPGCGELLF | DTDTWSLQIR | KTGAQTATDF | PHAIRIWYKT | 
    300:
    KPEGRSVTWT | SDQSGRPCVY | TVGSPINNRA | LFPCQEPPVA | MSTWQATVRA | 
    350:
    AASFVVLMSG | ENSAKPTQLW | EECSSWYYYV | TMPMPASTFT | IAVGCWTEMK | 
    400:
    METWSSNDLA | TERPFSPSEA | NFRHVGVCSH | MEYPCRFQNA | SATTQEIIPH | 
    450:
    RVFAPVCLTG | ACQETLLRLI | PPCLSAAHSV | LGAHPFSRLD | VLIVPANFPS | 
    500:
    LGMASPHIMF | LSQSILTGGN | HLCGTRLCHE | IAHAWFGLAI | GARDWTEEWL | 
    550:
    SEGFATHLED | VFWATAQQLA | PYEAREQQEL | RACLRWRRLQ | DEMQCSPEEM | 
    600:
    QVLRPSKDKT | GHTSDSGASV | IKHGLNPEKI | FMQVHYLKGY | FLLRFLAKRL | 
    650:
    GDETYFSFLR | KFVHTFHGQL | ILSQDFLQML | LENIPEEKRL | ELSVENIYQD | 
    700:
    WLESSGIPKP | LQRERRAGAE | CGLARQVRAE | VTKWIGVNRR | PRKRKRREKE | 
    750:
    EVFEKLLPDQ | LVLLLEHLLE | QKTLSPRTLQ | SLQRTYHLQD | QDAEVRHRWC | 
    800:
    ELIVKHKFTK | AYKSVERFLQ | EDQAMGVYLY | GELMVSEDAR | QQQLARRCFE | 
    819:
    RTKEQMDRSS | AQVVAEMLF
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    String:
    SMR:
    UniGene:
    KEGG:
    Pfam:
    Uniprot:
     
    FOR
    ELISA Kit for Human AP-O
    Cat.:
    E12538h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human AP-O
    Cat.:
    E12538m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human AP-O
    Cat.:
    E12538r
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human AP-O
    Cat.:
    U12538r
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human AP-O
    Cat.:
    U12538m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human AP-O
    Cat.:
    U12538h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    Polyclonal Antibody for Human AP-O
    Polyclonal Antibody for Human AP-O
    Polyclonal Antibody for Human AP-O
    Cat.:
    P12538Rb-h
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Monoclonal Antibody for Human AP-O
    Monoclonal Antibody for Human AP-O
    Monoclonal Antibody for Human AP-O
    Protein for Human AP-O
    Protein for Human AP-O
    Protein for Human AP-O

    R&D Technical Data

    s

    s

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    s
    s
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤6.4%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤9.1%

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤6.3%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤9.4%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤3.9%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤7.7%

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤3.9%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤7.7%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery

    Recovery was determined by spiking various levels of AMPO into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    103

    96-105

    Plasma

    101

    92-106

     

     

     

     

    Recovery was determined by spiking various levels of AMPO into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    95

    90-100

    Plasma

    96

    91-102

     

     

     

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Recovery was determined by spiking various levels of ACE into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    99

    91-103

    Plasma

    98

    93-106

     

     

     

     

    Recovery was determined by spiking various levels of ACE into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    99

    91-103

    Plasma

    98

    93-106

     

     

     

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of AMPO and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    98-107%

    95-111%

    97-109%

    94-110%

    EDTA plasma(n=5)

    93-108%

    97-105%

    95-107%

    96-106%

    heparin plasma(n=5)

    96-104%

     

    94-109%

    98-105%

    97-107%

     

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of AMPO and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    88-104%

    91-98%

    90-101%

    92-98%

    EDTA plasma(n=5)

    90-103%

    93-100%

    88-105%

    90-104%

    heparin plasma(n=5)

    92-102%

     

    91-102%

    92-101%

    93-98%

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of ACE and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    92-105%

    90-101%

    95-105%

    92-109%

    EDTA plasma(n=5)

    89-95%

    93105%

    89-94%

    90-106%

    heparin plasma(n=5)

    93-104%

     

    94-110%

    101-111%

    91-110%

     

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of ACE and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    92-105%

    90-101%

    95-105%

    92-109%

    EDTA plasma(n=5)

    89-95%

    93105%

    89-94%

    90-106%

    heparin plasma(n=5)

    93-104%

     

    94-110%

    101-111%

    91-110%

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      "Identification of human aminopeptidase O, a novel metalloprotease with structural similarity to aminopeptidase B and leukotriene A4 hydrolase."
      Diaz-Perales A. , Quesada V. , Sanchez L.M. , Ugalde A.P. , Suarez M.F. , Fueyo A. , Lopez-Otin C.
      J. Biol. Chem.280:14310-14317(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1);FUNCTION;ENZYME REGULATION;BIOPHYSICOCHEMICAL PROPERTIES;ENZYME ACTIVITY;TISSUE SPECIFICITY
      tissue: Brain.
    2. 2.
      "Complete sequencing and characterization of 21,243 full-length human cDNAs."
      Ota T. , Suzuki Y. , Nishikawa T. , Otsuki T. , Sugiyama T. , Irie R. , Wakamatsu A. , Hayashi K. , Sato H. , Nagai K. , Kimura K. , Makita H. , Sekine M. , Obayashi M. , Nishi T. , Shibahara T. , Tanaka T. , Ishii S. , more...
      Nat. Genet.36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3);NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 178-819 (ISOFORM 4)
      tissue: Teratocarcinoma.
      tissue: Testis.
    3. 3.
      "DNA sequence and analysis of human chromosome 9."
      Humphray S.J. , Oliver K. , Hunt A.R. , Plumb R.W. , Loveland J.E. , Howe K.L. , Andrews T.D. , Searle S. , Hunt S.E. , Scott C.E. , Jones M.C. , Ainscough R. , Almeida J.P. , Ambrose K.D. , Ashwell R.I.S. , Babbage A.K. , Babbage S. , Bagguley C.L. , more...
      Nature429:369-374(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    4. 4.
      "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
      The MGC Project Team
      Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2);NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 219-819 (ISOFORM 1)
      tissue: Lung.
      tissue: Muscle.
    Product Feedback Wall
    Hot Genes
    ALCAM ACE KSR2 ASPRO C19orf80 Gdf5 Trap1a Atf2
    Top Searches
    Ubiquitin-protein ligase Ubiquitin ELISA metalloproteinase Asprosin Tumor necrosis TRAP1A vitamin d
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    Twitter